What is Pfizer's cash & equivalents?

Pfizer (PFE) reported cash & equivalents of $1.76B in Q1 2026.

How has Pfizer's cash & equivalents changed year-over-year?

Pfizer's cash & equivalents increased by 18.8% year-over-year, from $1.48B to $1.76B.

What is the long-term trend for Pfizer's cash & equivalents?

Over 5 years (2020 to 2025), Pfizer's cash & equivalents has grown at a -8.1% compound annual growth rate (CAGR), from $1.83B to $1.2B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Pfizer PFE Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers SquibbBMY

$9.57B-12.0%

Eli LillyLLY

$5.28B+70.8%

Johnson & JohnsonJNJ

$20.42B+9.9%

Merck & Co.MRK

$5.4B-38.2%

AmgenAMGN

$559M+10.0%

Ionis PharmaceuticalsIONS

$173.38M-34.4%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$139.86B+1.2%

Enterprise value$202.53B+2.2%

P/E11.6×—

P/S2.2×0.0×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's cash & equivalents?: Pfizer (PFE) reported cash & equivalents of $1.76B in Q1 2026.
How has Pfizer's cash & equivalents changed year-over-year?: Pfizer's cash & equivalents increased by 18.8% year-over-year, from $1.48B to $1.76B.
What is the long-term trend for Pfizer's cash & equivalents?: Over 5 years (2020 to 2025), Pfizer's cash & equivalents has grown at a -8.1% compound annual growth rate (CAGR), from $1.83B to $1.2B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.